Thu, May 8, 11:32 AM (5 days ago)
**Rapport Therapeutics, Inc. (RAPP) Q1 2025 Financial Summary** **Financial Health & Performance Metrics:** - **Revenue:** No revenue reported as the company is in the clinical-stage and has not yet commercialized any products. - **Profit Margins:** The company reported a net loss of $24.1 million for Q1 2025, compared to a net loss of $22.7 million in Q1 2024. - **Cash Flow:** The company had cash, cash equivalents, and short-term investments of $285.4 million as of March 31, 2025, excluding restricted cash. The company expects this to be sufficient to fund operations through at least 12 months from the issuance date of the financial statements. - **Earnings Changes:** The net loss increased by $1.394 million compared to the same period last year. **Quarterly Performance Discussion:** - **Operating Expenses:** Total operating expenses were $27.108 million for Q1 2025, an increase of $10.014 million from Q1 2024. This includes $19.572 million in research and development expenses and $7.536 million in general and administrative expenses. - **Other Income (Expense):** The company reported other income of $3.045 million for Q1 2025, primarily from interest income, compared to an expense of $5.575 million in Q1 2024, which included a change in the fair value of preferred stock tranche right liability. **Trends & Uncertainties:** - **Clinical Development:** The company is conducting a Phase 2a proof-of-concept trial for RAP-219 in refractory focal epilepsy and plans to initiate additional trials for bipolar mania and diabetic peripheral neuropathic pain. - **Regulatory Uncertainties:** The FDA placed a clinical hold on the Phase 2a trial for RAP-219 in diabetic peripheral neuropathic pain, requesting additional information. - **Future Operations Impact:** The company expects to continue incurring significant losses as it advances its clinical development programs and seeks regulatory approvals. The company will need to raise additional capital to support its operations and growth strategy. **Target Audience:** Portfolio managers, Traders, Finance Professionals